2 ms·
That is the same with all post-market monitoring for drugs. And maybe we can do better because more nimble/startup approach in a small state
by niklas_anzinger 17d ago
That is the same with all post-market monitoring for drugs. And maybe we can do better because more nimble/startup approach in a small state
- ceejayoz 17d agoIsn't this pre-market, though?
- niklas_anzinger 17d agoRelative to the federal approval it's pre-market. In Montana, if your treatment is approved by a review board it's in market
- estearum 17d agoBut there are, obviously, proportionally way fewer bad outcomes created by drugs that pass Phases 2 and 3 than those that only pass Phase 1. The steepness of that attrition is literally the entire value prop of the law to begin with.